N4 Pharma strikes partnership deal for intracellular delivery
(Alliance News) - N4 Pharma PLC on Thursday said it has entered into a collaboration agreement with SRI International Inc.
Read moreMon, 29th Oct 2018 11:32
(Alliance News) - N4 Pharma PLC on Thursday said it has entered into a collaboration agreement with SRI International Inc.
Read moreN4 Pharma PLC - Derbyshire, England-based pharmaceutical company focused on the development of Nuvec - Posts revenue of GBP1,953 in 2023, compared to no revenue a year ago. Pretax loss widens to GBP1.4 million from GBP1.2 million. Looks ahead to the rest of 2024 with "great optimism."
Read more(Alliance News) - N4 Pharma PLC on Thursday reported that its novel delivery system for cancer treatment has shown promise, after a successful trial.
Read more(Sharecast News) - N4 Pharma announced a significant advancement in the development of Nuvec, an innovative delivery system tailored for cancer treatments, gene therapy, and vaccines, on Thursday.
Read moreN4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec - Reports an "encouraging" update from its Nuvec delivery system for cancer treatments, gene therapy and vaccines. It has completed in-vitro experiments combining epidermal growth factor receptor and polo like kinase 1 molecules onto a Nuvec nanoparticle, before testing it on lung cancer cells. "The work clearly shows that there is a strong beneficial effect at 48 hours on cellular inhibition compared to single dose siRNA, by combining both EGFR and PLK1 onto the same particle," N4 says.
Read more(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.
Read more(Sharecast News) - N4 Pharma, a pharmaceutical company developing the cancer vaccine delivery system Nuvec, announced on Friday that it has received confirmation from the University of Queensland regarding the granting of its patent for Nuvec in India.
Read moreN4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec - University of Queensland has informed the company that it has been notified by its Indian patent attorney of the granting of its patent for Nuvec in India. Nuvec is a novel silica nanoparticle delivery system for cancer treatments, gene therapy and vaccines. N4 Pharma says the granted patent in India is for a composition of matter patent for the particle itself, alongside the manufacturing process relating to how the particle is made. Says it matches the patents granted in the US, Canada, Europe, Japan, Australia and China.
Read more(Sharecast News) - N4 Pharma announced a significant development through its subsidiary Nanogenics on Tuesday, after Nanogenics inked a contract to initiate the formulation and sequence selection work for its ECP105 product, aimed at pre-clinical studies at King's College, London.
Read moreN4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec, a novel silica nanoparticle delivery system, for vaccines and therapeutics - Says subsidiary, Nanogenics Ltd, has signed a contract to start the formulation and sequence selection work to prepare its ECP105 product for testing in pre-clinical studies at King's College, London.
Read more(Sharecast News) - Pharmaceutical delivery system developer N4 Pharma reported significant progress in its research efforts to enhance viral vector performance using Nuvec on Monday.
Read more(Alliance News) - N4 Pharma PLC on Monday said that a series of experiments have shown that Nuvec can deliver increased transduction efficacy, when complexed with Adeno-Associated virus 8.
Read more(Alliance News) - Stock prices in London closed higher on Monday, after investors shrugged off hawkish comments from US Federal Reserve officials amid festive cheer.
Read more(Alliance News) - N4 Pharma PLC on Monday announced the successful oral administration of Nuvec with a DNA plasmid after receiving promising results from its research programme with the University of Queensland.
Read more(Sharecast News) - N4 Pharma updated the market on Monday on its ongoing research efforts related to Nuvec, its delivery system designed for cancer treatments and vaccines.
Read more